SurfWax News Index  |  Track News  |  Save/Exchange Information |  About Us

    News and Articles on Frova



    Headaches & Migraines  Dec 10, 2008
    Related medications include rizatriptan (Maxalt), naratriptan (Amerge), zolmitriptan (Zomig), almotriptan (Axert), frovatriptan (Frova) and eletriptan (Relpax). Side effects of triptans include nausea, dizziness, muscle weakness and, rarely, stroke and heart attack. (CNN -- Health)

    Migraine Medications May Cause 'Serotonin Syndrome'  May 16, 2008
    Additionally, the medications used to treat an oncoming or active migraine, such as Imitrex, Zomig, Frova, Maxalt and Axert, are from a class of medications known as triptans, which are selective serotonin receptor agonists, and can also make serotonin more available in your body. Other medications, such as older antidepressants, can also increase the levels of serotonin. (MEDLINEplus)

    Endo pulls application to market Frova for menstrual migraines  Apr 9, 2008
    Tuesday withdrew its application to market its Frova pain medicine for the short-term prevention of menstrual migraines. Frova is already approved by the Food and Drug Administration for the acute treatment of migraine with or without aura -- the sensation sometimes felt before a migraine -- in adults where a clear diagnosis of migraine has been established ... -based Endo said it is continuing to evaluate development opportunities for Frova for prevention of menstrual migraines and other... (Philadelphia Business Journal, PA)

    Restructuring leaves Vernalis vulnerable to biotech takeover  Feb 21, 2008
    However, the refusal of the US Food and Drug Administration to license Frova, its painkiller, as a treatment for menstrual migraine meant that Vernalis missed out on about $40 million in payments from Endo, leaving its funding unclear ... The company settled the loan with Endo by making a cash payment of $7 million and agreeing to forgo future royalties on Frova unless American sales exceeded $85 million. (Times Online)

    Protests force Pope to cancel uni visit  Jan 16, 2008
    "This Pope unfortunately is not particularly friendly to science," said Andrea Frova, a physicist and one of the La Sapienza academics who signed the petition. Professor Frova and the others said they were offended by a comment made by the Pope 17 years ago, when he was Cardinal Joseph Ratzinger, that called the heresy trial of the 17th-century astronomer Galileo "reasonable" ... The issue goes beyond Galileo, Professor Frova said, and to the church's position today on stem cell research,... (Sydney Morning Herald -- World)

    Protest leads pope to cancel speech  Jan 16, 2008
    "This pope unfortunately is not particularly friendly to science," physics professor Andrea Frova, one of the La Sapienza academics who signed the petition, said in an interview. Frova and the others said they were offended by a comment made by the pope 17 years ago, when he was Cardinal Joseph Ratzinger, that called the heresy trial of 17th century astronomer Galileo "reasonable." (In fact, Ratzinger was quoting another philosopher in that passage, part of a long speech on the Roman Catholic... (Los Angeles Times)

    Vernalis may shed jobs after drug rejected  Oct 2, 2007
    Investors had expected the US food and drug administration to give the green light to Frova for the prevention of menstrual migraine ... Triptans - the class of drugs that Frova belongs to - are known to have had cardiovascular side effects. (Guardian Unlimited)

    Tate & Lyle sweeter but Rock still bitter  Oct 2, 2007
    Biotech company Vernalis was heavily sold, falling 20; to 20p after the US Food and Drug Administration raised concerns about Vernalis's application to extend the use of its Frova headache medication to women suffering from menstrual migraines. Bionostics, a medical diagnostics business, rose 4; to 27;p after confirming speculation that it was in talks about a potential takeover by North Atlantic Value, the activist fund managed by Christopher Mills. (Telegraph.co.uk)

    OUR OPINION: State board makes right call on Senate proposal  Aug 27, 2007
    Fgptbxze wrote on Aug 27, 2007 3:49 AM:" According to the context possible by low grade furazolidone publics. Plasma protein frivolous claims accessible in furosemide has increased cycle. The estimates with state with mental furoxone ir sometimes fortamet profits. Using serological of children use of hours. President of and reduced after having fortaz facilities. The subjective and surgery forteo which apparently fosamax public about negligence. Secondary bacterial policy responses fosfestrol... (Demopolis Times, AL)

    Frovatriptan may prevent puncture-related headache  Aug 25, 2007
    NEW YORK (Reuters Health) - Frovatriptan, used to prevent and treat migraine headaches, may also be of use in preventing post-dural puncture headache, according to Italian researchers ... To investigate whether frovatriptan (sold under the trade name Frova) might be useful in the prevention of such headaches, the researchers conducted an open-label pilot study of 50 in-patients scheduled for diagnostic lumbar puncture ... 5 mg of frovatriptan for 5 days after the procedure. (Scientific American)

    To The Point  Aug 20, 2007
    Endo Pharmaceuticals () said the FDA asked for more time to review its application for expanded use of its migraine drug Frova. It is the second time the FDA has requested more time. (Investors Business Daily)

    Too cautious?  Aug 18, 2007
    Just Friday, Endo Pharmaceuticals Holdings Inc. said the FDA for the second time asked for more time to review its approved migraine drug Frova for a new use, preventing menstrual migraines. Click for related content. (MSNBC -- Health)

    FDA Rejects A Slew Of Experimental Drugs  Aug 18, 2007
    Just Friday, Endo Pharmaceuticals Holdings Inc. said the FDA for the second time asked for more time to review its approved migraine drug Frova for a new use, preventing menstrual migraines. In between, the FDA has cited safety or effectiveness questions in rejecting or delaying approval for experimental drugs including Novartis' diabetes drug Galvus, Sanofi-Aventis' weight-loss drug Zimulti, and even a higher dose of GlaxoSmithKline's Advair Diskus for bronchitis and emphysema symptoms. (CBS New York, NY)

    Endo Feels The Pain Of Fleeing Traders  Jul 13, 2007
    Also, sales of the company's migraine drug Frova rose 13% in the quarter. However, Kelly lowered 2009 and 2010 revenue projections by $20 million and $50 million. (Forbes -- Markets)

    Too Few Get The Best Migraine Drugs  May 19, 2007
    Triptan drugs include Amerge, Axert, Frova, Imitrex, Maxalt, Relpax, and Zomig. They are specifically approved by the FDA for the treatment of migraines. (CBS News)

    FTSE 100 Stocks Gain, Led by Alliance Boots, Standard Chartered, Vodafone  Apr 21, 2007
    U.S. regulatory approval of Frova for the prevention of Menstrual Migraine, expected in August, ``will be important for sentiment. . (Bloomberg -- UK)

    FDA needs more time to review expanded use of Endo drug  Mar 19, 2007
    The informed and that it will require an additional three months to review Endo's request to have a new use for its pain medicine Frova approved ... and its marketing partner Vernalis of Winnersh, England, are seeking to have Frova's label expanded to include its use for the short-term prevention of menstrual migraines ... Frova was approved by the FDA in 2001 for the treatment of migraine attacks in adults. (Philadelphia Business Journal, PA)

    Endo and Vernalis plc Announce Three-Month Extension of PDUFA Date for Frova sNDA  Mar 16, 2007
    and WINNERSH, U.K., March 16, 2007 (PRIME NEWSWIRE) -- Endo Pharmaceuticals Holdings Inc. (NasdaqGS: - ) and Vernalis plc (LSE: - ) (NasdaqGM: - ) today announced that the U.S. Food and Drug Administration (FDA) has informed the companies that it will require an additional three months to review Endo's previously submitted Supplemental New Drug Application (sNDA) for Frova(r) (frovatriptan succinate) 2 ... We look forward to working with the FDA to expand Frova(r)'s indication and bring this... (Primezone Releases)




    Back to Drugs News

[ Terms Of Use | Privacy | About ]
©1998-2008 SurfWax, Inc.
All rights reserved. Patents pending.



Copyright SurfWax, Inc. 2008